Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes

TAKASHI KADOWAKI*, MITSUYOSHI NAMBA**, AYUKO YAMAMURA***, HIDEAKI SOWA***, ANNE M. WOLKA†, ROBERT G. BRODOWS‡

* Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
** Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya Hyogo, 663-8501, Japan
*** Lilly Research Laboratories Japan, Eli Lilly Japan KK, Sannomiya Plaza Bldg., 7-1-5, Isogamidori, Chuo-ku, Kobe, 651-0086, Japan
† Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, 46285, United States

Abstract. This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite therapeutic doses of sulfonylurea (SU), SU plus biguanide, or SU plus thiazolidinedione. Patients were randomly assigned to placebo (N = 40), 2.5 µg (N = 38), 5 µg (N = 37), or 10 µg (N = 38) exenatide administered subcutaneously twice daily (BID). Patients randomly assigned to 10 µg exenatide received 5 µg BID for the first 4 weeks, with the dose escalated to 10 µg BID for the final 8 weeks. Patients were 60.3 ± 9.7 years old, with body mass index 25.3 ± 4.3 kg/m² and hemoglobin A1c (HbA1c) 8.0 ± 0.8%. Baseline-to-endpoint HbA1c changes (%) were +0.02 ± 0.1 (placebo), -0.9 ± 0.1 (2.5 µg), -1.2 ± 0.1 (5 µg), and -1.4 ± 0.1 (10 µg) (all p < 0.001 vs. placebo). Of patients with baseline HbA1c ≥7%, 5.1% (placebo), 50.0% (2.5 µg), 71.4% (5 µg), and 79.4% (10 µg) achieved HbA1c <7% at endpoint (p < 0.001, trend test). Baseline-to-endpoint fasting plasma glucose changes (mg/dL) were +6.0 ± 4.8 (placebo), -18.6 ± 5.7 (2.5 µg), -25.0 ± 7.0 (5 µg), and -28.9 ± 5.9 (10 µg) (all p ≤ 0.001 vs. placebo). Treatment-emergent adverse events were mostly mild; dose-dependent increases in incidence were observed for hypoglycemia, nausea, anorexia, decreased appetite, and diarrhea (all p ≤ 0.044, trend test). Over 12 weeks, exenatide dose-dependently improved glycemic control in Japanese patients with type 2 diabetes.

Key words: Exenatide, Dose response, Glycemic control, Japan, Type 2 diabetes

(JAPAN) is among the top 10 countries estimated to have had the greatest numbers of people with diabetes in the year 2000 (6.8 million) and is also among the top 10 countries predicted to have the greatest numbers of people with diabetes in the year 2030 (8.9 million) [1]. The combination of Westernized lifestyle boards for Novo Nordisk, Novartis, and Eli Lilly and Company; has received consulting fees from Novo Nordisk, Novartis, and Merck; and has received financial support or grants to conduct research from Novo Nordisk and Eli Lilly and Company. M. Namba has participated in advisory boards for Novo Nordisk and Novartis; has received consulting fees from Novo Nordisk; and has received financial support or grants to conduct research from Novo Nordisk, Eli Lilly and Company, and Banyu Pharmaceutical Company, Ltd. A. Yamamura and H. Sowa are employees and shareholders of Eli Lilly and Company (Kobe, Japan). A. M. Wolka and R. G. Brodows are employees and shareholders of Eli Lilly and Company (Indianapolis, Indiana, United States).
changes with the Japanese ‘thrifty’ genotype, which can contribute to imbalances in energy expenditure, glucose homeostasis, and glucose disposal efficiency in modernized societies, have been implicated in the increasing prevalence of diabetes in Japan [2-4], despite a low prevalence of obesity compared with Western societies [5].

Development of pharmacological therapies with novel mechanisms of action is of clinical interest for the treatment of Japanese patients with type 2 diabetes. Exenatide is the first in a class of antidiabetic agents known as the glucagon-like peptide-1 (GLP-1) receptor agonists. Exenatide shares several metabolic effects with the naturally occurring human incretin gut hormone GLP-1, including glucose-dependent enhancement of insulin secretion, suppression of elevated glucagon secretion, slowing of gastric emptying, and enhancement of satiety [6, 7].

A randomized, single-blind, placebo-controlled, parallel study has previously evaluated the pharmacokinetics, pharmacodynamics, tolerability, and safety of 2.5 µg, 5 µg, 10 µg, and 15 µg exenatide over a period of 10 days in a group of 40 Japanese patients with type 2 diabetes being treated with either diet and exercise alone or oral antidiabetic agents [8]. This study showed that, at doses up to 10 µg, exenatide dose-dependently reduced plasma glucose and was generally well tolerated. The highest dose of exenatide, 15 µg, was poorly tolerated due to nausea and vomiting [8].

The current randomized, partial double-blind, placebo-controlled, parallel study, conducted over a period of 12 weeks in 153 Japanese patients whose type 2 diabetes was suboptimally controlled despite therapeutic doses of oral antidiabetic agent(s), was designed to further evaluate the dose-dependent effects on glycemic control and safety of 2.5 µg, 5 µg, and 10 µg exenatide.

Patients and Methods

Patients

Japanese patients were included if they were between 20 and 75 years of age and had type 2 diabetes and a body weight ≥50 kg. Patients were required to have been managing their type 2 diabetes with therapeutic doses of a sulfonylurea (SU) alone, SU plus a biguanide (BG), or SU plus a thiazolidinedione (TZD) for at least 3 months prior to screening. Patients using an α-glucosidase inhibitor (α-GI) or a meglitinide derivative could be included in this study, but were required to discontinue these oral antidiabetic agents prior to initiation of study drug. Despite taking therapeutic doses of oral antidiabetic agent(s), patients were required to have suboptimal glycemic control, as evidenced by a hemoglobin A1c (HbA1c) ranging from 7% to 10% for patients treated with SU alone, SU plus a BG, or SU plus a TZD, or from 6.5% to 9.5% for patients treated with an α-GI or a meglitinide derivative.

Exclusion criteria included treatment with any exogenous insulin or drug directly affecting gastrointestinal motility within the 3 months prior to screening; clinically significant renal or hepatic disease; blood pressure ≥160/100 mmHg; hospitalization for cardiac disease within the year prior to inclusion in the study; clinically significant history of or active digestive disease within the year prior to inclusion in the study; active or untreated malignancy or remission from clinically significant malignancy for <5 years; obvious hyperglycemia as evidenced by self-monitored blood glucose ≥250 mg/dL in the fasting state or ≥350 mg/dL measured at any time; or >1 severe hypoglycemic episode requiring the assistance of another person within the 3 months prior to screening. Female patients of childbearing age were excluded if they were pregnant at the time of enrollment, intended to become pregnant during the study, had not practiced a reliable method of birth control for the 3 months prior to screening, or did not agree to continue practicing a reliable method of birth control during the study.

Study design

This was a 12-week, phase 2, randomized, placebo-controlled, parallel study conducted at 20 centers in Japan. Patients, investigators, and the sponsor were unblinded to the injection volume but blinded to the distinction between exenatide and placebo. After screening, α-GI and meglitinide derivatives had to be discontinued and washed out for a period of 2 to 3 weeks.

Patients were randomly assigned to subcutaneous injections of placebo (N = 40), 2.5 µg exenatide (N = 38), 5 µg exenatide (N = 37), or 10 µg exenatide (N = 38) twice daily using a dynamic allocation algorithm that involved allocation factors including HbA1c val-
Statistical analyses

Sample size was determined based on the results from previous clinical studies performed in the United States [10-13]. A sample size of at least 33 patients per treatment group was needed to ensure power exceeding 90% to detect a significant difference between the 10 µg exenatide and placebo treatment groups by Williams’ test, with a one-sided significance level of 2.5%. Considering differences between the patient population in the current Japanese study vs. the previous studies conducted in the United States, the target number of patients per treatment group was 35.

The primary efficacy measure was change in HbA1c from baseline to endpoint. Endpoint was defined as week 12 for patients who completed the study or the last observation carried forward for patients who discontinued early. The primary efficacy analysis was based on Williams’ test to identify the minimal dose of exenatide that yielded a significant difference in HbA1c vs. placebo, assuming a monotonicity of the dose-response relationship with regard to the mean change in HbA1c over the dose range of 0 µg (placebo) to 10 µg exenatide. The analysis was performed in the order of the 10 µg, 5 µg, and 2.5 µg exenatide treatment groups until a significant difference was no longer detected. A one-sided significance level of 2.5% was used in these statistical analyses.

Data are presented for the full analysis set, which includes all randomized patients who received at least one dose of study drug and who had post-baseline data available. All tests of treatment effects were conducted at a two-sided significance level of 5%, unless otherwise stated. Unless otherwise stated, data are presented as means ± standard errors.

Results

Patient disposition and baseline characteristics

Patient disposition is shown in Table 1. Of 153 randomized patients, 151 were included in the full analysis set. Two patients withdrew their consent and did not receive study drug. Overall, 90.7% (137/151) of patients in the full analysis set completed the study.

Patients in the full analysis set were generally balanced among treatment groups with respect to baseline characteristics (Table 1). Using a two-sided sig-
for all exenatide treatment groups, but remained essentially unchanged over the same period for placebo (Figure 1A).

HbA1c changes from baseline to endpoint were -0.9 ± 0.1% ($p < 0.001$), -1.2 ± 0.1% ($p < 0.001$), and -1.4 ± 0.1% ($p < 0.001$) for the 2.5 µg, 5 µg, and 10 µg exenatide treatment groups, respectively, compared with +0.02 ± 0.1% for placebo (exenatide vs. placebo, Williams’ test).

Of patients who had HbA1c ≥ 7.0% at baseline, 50.0% (16/32), 71.4% (25/35), and 79.4% (27/34) in the 2.5 µg, 5 µg, and 10 µg exenatide treatment groups achieved HbA1c < 7.0% at endpoint, compared with

<table>
<thead>
<tr>
<th>Table 1. Patient disposition and baseline characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
</tr>
<tr>
<td>All randomized</td>
</tr>
<tr>
<td>Full analysis set</td>
</tr>
<tr>
<td>Completed⁠⁺</td>
</tr>
<tr>
<td>Discontinued, total⁠⁺</td>
</tr>
<tr>
<td>Due to adverse event</td>
</tr>
<tr>
<td>Due to protocol violation</td>
</tr>
<tr>
<td>Baseline characteristics⁠⁺</td>
</tr>
<tr>
<td>Gender (% male)</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Weight (kg)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
</tr>
<tr>
<td>Duration of type 2 diabetes (years)</td>
</tr>
<tr>
<td>HbA1c (%)</td>
</tr>
<tr>
<td>Fasting plasma glucose (mg/dL)</td>
</tr>
</tbody>
</table>

Data are N (%) or means ± standard deviations. *One patient randomized to this group discontinued prior to receiving study drug and was excluded from the full analysis set. †Data are for the full analysis set. ⁠⁺$p$ for comparison among the treatment groups (chi-square test for categorical variables or one-way ANOVA for continuous variables). α-GI = α-glucosidase inhibitor. ANOVA = analysis of variance. BG = biguanide. HbA1c = hemoglobin A1c. HDL = high-density lipoprotein. LDL = low-density lipoprotein. SU = sulfonylurea. TZD = thiazolidinedione.

Significance level of 15%, significant differences among the treatment groups were observed for duration of type 2 diabetes ($p = 0.032$) and body weight ($p = 0.087$) at baseline (one-way analysis of variance [ANOVA]). These differences would not be expected to affect the primary efficacy evaluation.

**Glycemic control**

A reduction from baseline in HbA1c was apparent by week 4 for all exenatide treatment groups, but not placebo (Figure 1A). HbA1c values decreased progressively in a dose-dependent manner over 12 weeks for all exenatide treatment groups, but remained essentially unchanged over the same period for placebo (Figure 1A).

HbA1c changes from baseline to endpoint were -0.9 ± 0.1% ($p < 0.001$), -1.2 ± 0.1% ($p < 0.001$), and -1.4 ± 0.1% ($p < 0.001$) for the 2.5 µg, 5 µg, and 10 µg exenatide treatment groups, respectively, compared with +0.02 ± 0.1% for placebo (exenatide vs. placebo, Williams’ test).

Of patients who had HbA1c ≥ 7.0% at baseline, 50.0% (16/32), 71.4% (25/35), and 79.4% (27/34) in the 2.5 µg, 5 µg, and 10 µg exenatide treatment groups achieved HbA1c < 7.0% at endpoint, compared with
Exenatide for Type 2 Diabetes in Japan

419

SU dose reduction or discontinuation and HbA1c

An SU dose reduction or discontinuation following a documented hypoglycemic episode was performed for 2.5% (1/40), 2.7% (1/37), 27.0% (10/37), and 48.6% (18/37) of patients treated with placebo, 2.5 µg, 5 µg, and 10 µg exenatide, respectively. Discontinuations (as opposed to dose reductions only) accounted for no patients treated with placebo or 2.5 µg exenatide, 2 of the 10 patients treated with 5 µg exenatide, and 5 of the 18 patients treated with 10 µg exenatide.

In the 5 µg exenatide group, the reduction in HbA1c from baseline to endpoint was -1.1 ± 0.2% for patients with an SU dose reduction or discontinuation vs. -1.3 ± 0.1% for patients without an SU dose reduction or discontinuation. In the 10 µg exenatide group, the reduction in HbA1c from baseline to endpoint was -1.2 ± 0.2% for patients with an SU dose reduction or discontinuation vs. -1.6 ± 0.2% for patients without an SU dose reduction or discontinuation.

Body weight

The greatest reduction in body weight after 12 weeks was observed for the 10 µg exenatide treatment group, followed by placebo and then 5 µg exenatide. Body weight remained essentially unchanged from baseline to 12 weeks for the 2.5 µg exenatide treatment group (Figure 2).
Table 2. Change in serum lipids from baseline to endpoint

<table>
<thead>
<tr>
<th></th>
<th>Placebo  N = 40</th>
<th>2.5 µg exenatide N = 37</th>
<th>5 µg exenatide N = 37</th>
<th>10 µg exenatide N = 37</th>
<th>p&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>+1.7 ± 2.8</td>
<td>-4.0 ± 4.4</td>
<td>-9.3 ± 4.2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>-15.7 ± 5.4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.029</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dL)</td>
<td>+0.8 ± 0.9</td>
<td>-3.4 ± 1.0&lt;sup&gt;c&lt;/sup&gt;</td>
<td>-3.7 ± 1.2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>-5.7 ± 1.4&lt;sup&gt;c&lt;/sup&gt;</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dL)</td>
<td>+0.8 ± 2.8</td>
<td>-4.3 ± 3.9</td>
<td>-4.4 ± 3.3</td>
<td>-1.3 ± 3.6</td>
<td>0.651</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>-24.5 ± 17.8</td>
<td>-0.4 ± 16.4</td>
<td>-32.5 ± 14.5</td>
<td>-61.9 ± 34.9</td>
<td>0.292</td>
</tr>
</tbody>
</table>

Data are means ± standard errors for the full analysis set. *p for comparison among the treatment groups (one-way ANOVA). <sup>b</sup>Significant difference between exenatide and placebo (both p ≤ 0.031, Student’s t test). <sup>c</sup>Significant difference between exenatide and placebo (all p ≤ 0.003, Student’s t test). ANOVA = analysis of variance. HDL = high-density lipoprotein. LDL = low-density lipoprotein.

Table 3. Treatment-emergent adverse events reported in ≥10% of patients in any treatment group

<table>
<thead>
<tr>
<th>MedDRA-preferred term</th>
<th>Placebo  N = 40</th>
<th>2.5 µg exenatide N = 37</th>
<th>5 µg exenatide N = 37</th>
<th>10 µg exenatide N = 37</th>
<th>p&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>0 (0.0)</td>
<td>4 (10.8)</td>
<td>3 (8.1)</td>
<td>13 (35.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0 (0.0)</td>
<td>2 (5.4)</td>
<td>5 (13.5)</td>
<td>3 (8.1)</td>
<td>0.067</td>
</tr>
<tr>
<td>Constipation</td>
<td>2 (5.0)</td>
<td>4 (10.8)</td>
<td>4 (10.8)</td>
<td>3 (8.1)</td>
<td>0.627</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>0 (0.0)</td>
<td>1 (2.7)</td>
<td>4 (10.8)</td>
<td>3 (8.1)</td>
<td>0.044</td>
</tr>
<tr>
<td>Stomach discomfort</td>
<td>1 (2.5)</td>
<td>2 (5.4)</td>
<td>4 (10.8)</td>
<td>3 (8.1)</td>
<td>0.212</td>
</tr>
<tr>
<td>Abdominal distention</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>4 (10.8)</td>
<td>2 (5.4)</td>
<td>0.055</td>
</tr>
<tr>
<td>Anorexia</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>1 (2.7)</td>
<td>5 (13.5)</td>
<td>0.002</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>3 (8.1)</td>
<td>5 (13.5)</td>
<td>0.003</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>11 (27.5)</td>
<td>9 (24.3)</td>
<td>3 (8.1)</td>
<td>7 (18.9)</td>
<td>0.142</td>
</tr>
<tr>
<td>Blood glucose decreased</td>
<td>4 (10.0)</td>
<td>3 (8.1)</td>
<td>8 (21.6)</td>
<td>8 (21.6)</td>
<td>0.065</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>4 (10.0)</td>
<td>10 (27.0)</td>
<td>16 (43.2)</td>
<td>20 (54.1)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>


A significant difference among the treatment groups was observed for change in body weight from baseline to endpoint (p = 0.004, one-way ANOVA). Body weight changes from baseline to endpoint were +0.08 ± 0.2 kg (p = 0.018), -0.2 ± 0.3 kg (p = 0.224), and -1.3 ± 0.3 kg (p = 0.148) for the 2.5 µg, 5 µg, and 10 µg exenatide treatment groups, respectively, compared with -0.7 ± 0.2 kg for placebo (exenatide vs. placebo, Student’s t test).

Serum lipids

Table 2 shows the change in serum lipids from baseline to endpoint. A significant difference among the treatment groups was observed for change in total cholesterol (p = 0.029) and change in high-density lipoprotein cholesterol (p < 0.001) from baseline to endpoint (one-way ANOVA). Reductions in total cholesterol were significantly greater for 5 µg exenatide (p = 0.031) and 10 µg exenatide (p = 0.005) vs. placebo (Student’s t test). Also, reductions in high-density lipoprotein cholesterol were significantly greater for 2.5 µg exenatide (p = 0.002), 5 µg exenatide (p = 0.003), and 10 µg exenatide (p < 0.001) vs. placebo (Student’s t test). No significant differences were observed between exenatide and placebo or among the treatment groups for changes in low-density lipoprotein cholesterol or triglycerides from baseline to endpoint.

Adverse events and hypoglycemia

Overall, 81.5% (123/151) of patients reported ≥1 treatment-emergent adverse event (placebo: 65.0% [26/40]; 2.5 µg exenatide: 78.4% [29/37]; 5 µg exenatide: 89.2% [33/37]; and 10 µg exenatide: 94.6% [35/37]). A dose-dependent increase was observed for
Exenatide For Type 2 Diabetes in Japan

Discussion

Over 12 weeks, exenatide improved HbA1c and fasting plasma glucose in Japanese patients whose type 2 diabetes was suboptimally controlled despite therapeutic doses of oral antidiabetic agent(s). Significant dose-dependent responses were observed for doses ranging from 2.5 µg to 10 µg.

Patients in the current study had type 2 diabetes on average for 10 to 15 years, with mean HbA1c values at baseline of 7.9% to 8.1%, indicating a moderately advanced stage of type 2 diabetes. The reductions in Hba1c (-0.9%, -1.2%, and -1.4%) and fasting plasma glucose (-18.6 mg/dL, -25.0 mg/dL, and -28.9 mg/dL) observed from baseline to endpoint for the 2.5 µg, 5 µg, and 10 µg exenatide treatment groups, respectively, were dose-dependent and also clinically relevant for all exenatide treatment groups. When evaluating effects on glycemic control, it is valuable to ascertain the proportion of patients who achieved a target Hba1c. In this study, exenatide dose-dependently enabled a greater proportion of patients (50.0% to 79.4%) to achieve an Hba1c value of <7.0% at endpoint than did placebo (5.1%). The positive effects of exenatide on glycemic control in Japanese patients with type 2 diabetes are consistent with those from previous placebo-controlled studies evaluating 5 µg and 10 µg exenatide combined with oral antidiabetic agents [10-12, 14].

In this group of Japanese patients, who had mean body weights of 65 to 71 kg at baseline, exenatide appeared to have a neutral effect on body weight, as compared with placebo, during the study. This apparent neutral effect of exenatide on body weight is notable since other antidiabetic therapies, including SU, TZDs, and insulins, can cause weight gain in patients with type 2 diabetes [15]. The reasons for the unexpected weight loss (-0.7 kg) with placebo observed in this study are not known. Body weight reductions of -0.9 to -2.2 kg have been observed with exenatide during previous placebo-controlled studies of 5 µg and 10 µg exenatide combined with oral antidiabetic agents [10-12, 14]. However, patients who participated in these previous studies were primarily Caucasian rather than Japanese and had greater baseline body mass indexes (33 to 34 kg/m²), on average, than patients in the current study (25 kg/m²).

The prevention of diabetic complications requires
control of factors other than glycemia, including lipid profiles. A prospective cohort study of 4014 elderly Japanese patients with type 2 diabetes has shown that tight lipid control reduces the incidence of vascular events in this population [16]. Previous placebo-controlled studies have shown that exenatide combined with oral antidiabetic agents has a neutral effect on serum lipids over the short term in predominantly Caucasian populations [10, 11, 14]. In this study of Japanese patients, clinically relevant reductions in total cholesterol from baseline to endpoint were observed for the 5 µg (-9.3 mg/dL) and 10 µg (-15.7 mg/dL) exenatide treatment groups. Reductions in high-density lipoprotein cholesterol with 2.5 µg, 5 µg, and 10 µg exenatide, despite being significantly greater than with placebo, were modest and the mean values remained in the normal range after 12 weeks. A large degree of variability in triglyceride levels was observed within the treatment groups, making these data difficult to interpret. Additional longer-term studies appear warranted to further evaluate the effects of exenatide on serum lipids in Japanese patients with type 2 diabetes.

The safety profile observed in this study was consistent with previous reports for GLP-1 agonists, for both Japanese and non-Japanese populations [8-14, 17-19]. Consistent with placebo-controlled studies of exenatide combined with oral antidiabetic agents performed in predominantly Caucasian populations [10-12, 14] and a study of exenatide performed in 40 Japanese inpatients with type 2 diabetes being treated with either diet and exercise alone or oral antidiabetic agents [8], the treatment-emergent adverse events reported in this study were primarily gastrointestinal in nature, with significant dose-dependent increases in the incidences of nausea, anorexia, decreased appetite, and diarrhea.

A significant dose-dependent increase in the incidence of hypoglycemia was also observed in the current study. Exenatide enhances insulin secretion from pancreatic β-cells in a glucose-dependent fashion, wherein insulin secretion decreases as glucose levels normalize [6, 7]. This mechanism reduces exenatide’s potential to cause hypoglycemia. However, up to 54.1% of exenatide-treated patients reported hypoglycemia during this study. This observation is likely because all patients were taking a concomitant SU, with or without additional concomitant oral agents (BG or TZD). In two previous placebo-controlled studies of exenatide combined with oral antidiabetic agents performed in predominantly Caucasian populations, concomitant SUs have been implicated in increasing the incidence of hypoglycemia when coupled with lower ambient glycemia and increasing exenatide dose [10, 12].

SU is the most common oral antidiabetic agent used as monotherapy in Japan, and is also frequently used concomitantly with other oral antidiabetic agents. During a cross-sectional study of 17,000 Japanese patients with diabetes, 37% to 43% of patients on oral therapy were taking an SU alone, and an additional 35% were taking an SU in combination with a BG, an α-GI, or a BG plus an α-GI [20]. This prominent use of SU in Japanese patients is consistent with the pathology of the development of type 2 diabetes in this population, which has been characterized primarily by insufficient insulin secretion from pancreatic β-cells [3, 21].

A proactive approach to SU dose management has been suggested in order to reduce the incidence of hypoglycemia in exenatide-treated patients [12]. However, proactive SU dose adjustments were not performed in the current study because, according to the protocol, SU could be discontinued or the dose reduced only after a documented hypoglycemic episode. Dosing guidelines for the concomitant use of exenatide and SU in Japanese patients would be useful in clinical practice and should be devised.

Because of the potentially immunogenic properties of any protein or peptide pharmaceutical, antibodies to exenatide were measured. In the current study, the presence of antibodies to exenatide had no clinically relevant effects on glycemic control or safety in Japanese patients. Previous studies in predominantly Caucasian populations have demonstrated that antibody titers diminish over time in most patients [22]; longer-term studies would be required to evaluate antibody titers over time in Japanese patients.

This study has several limitations. First, the study design was partial double-blind, in that patients, investigators, and the sponsor were blinded to the distinction between exenatide and placebo, but unblinded to injection volume. A full double-blind design may have been more robust. Also, there were no standardized diet and exercise recommendations in the current study.

In conclusion, the data show that the effects of exenatide twice daily on glycemic control are similar for Japanese and Caucasian patients and furthermore...
support the use of exenatide at the maximal tolerable dose, up to 10 µg twice daily, in the treatment of Japanese patients with type 2 diabetes. Additional studies of longer duration are required to further evaluate the efficacy and safety of exenatide in Japanese patients with type 2 diabetes.

Acknowledgment

This study was supported by Amylin Pharmaceuticals, Inc. (San Diego, California, United States) and Eli Lilly and Company (Indianapolis, Indiana, United States). Hirofumi Shigeta, MD, PhD (formerly of Eli Lilly Japan KK, Kobe, Japan), provided medical advice and support during the writing of this manuscript.

References

the LEAD (liraglutide effect and action in diabetes)-2 study. *Diabetes Care* 32:84-90.


